HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by DROBNIEWSKI, F.A. Articles by HARRIS, G.S. Search for Related Content PubMed PubMed Citation Articles by DROBNIEWSKI, F.A. Articles by HARRIS, G.S. Agricola Articles by DROBNIEWSKI, F.A. Articles by HARRIS, G.S.

A clinical, microbiological and economic analysis of a national service for the rapid molecular diagnosis of tuberculosis and rifampicin resistance in Mycobacterium tuberculosis

Public Health Laboratory Service Mycobacterium Reference Unit, Dulwich Public Health Laboratory and Department of Microbiology, Guy's King's and St Thomas’ School of Medicine, London SE22 8QF

Corresponding author: Dr F. A. Drobniewski.

Received 19 July 1999; accepted 1 Sept. 1999.

Abstract

A clinical, microbiological and economic study of a national rapid molecular service for the identification of Mycobacterium tuberculosis and the determination of rifampicin resistance in smear-positive sputum samples (and other primary specimens) was performed. Ninety-one primary specimens, of which 55 were smear-positive sputum, were examined by molecular and conventional assays. Concordance of molecular results from smear-positive sputum specimens with tuberculosis diagnosis and rifampicin resistance by conventional analysis was 52 (94.5%) of 55 and 44 (91.7%) of 48, respectively. Concordance of molecular analysis on all primary specimens was 81 (89.0%) of 91 (diagnosis) and 55 (90.2%) of 61 (rifampicin resistance). Approximately 28 days were saved in the time to diagnosis by using the molecular assay. Hospitals can reduce the cost of inappropriate isolation of patients with risk factors for multiple drug-resistant tuberculosis (MDRTB) who subsequently are shown to have drug-sensitive tuberculosis. At one hospital potential annual savings were between £50 000 and £150 000. Of the nine MDRTB cases identified, all had a previous diagnosis of tuberculosis, 78% were born overseas, 44% were known to be non-compliant with therapy, but only one case (12.5%) was HIV positive. HIV status was not significantly different between MDRTB and drug-sensitive tuberculosis cases. Over 75% of specimens were taken while the patient was on therapy. Isolates from >50% of the MDRTB cases were resistant to three or more drugs and one was resistant to seven drugs. All patients were placed on additional therapy once the molecular result was known; this was subsequently modified based on the results of in-vitro drug susceptibility testing. All survived at least 6 months of follow-up. There was no difference in the proportion of successful cultures from smear-positive samples from patients with drug-sensitive tuberculosis or MDRTB who were on therapy. Molecular rifampicin resistance assays are reliable for diagnosis in cases with smear-positive disease.

This article has been cited by other articles:

				M Taegtmeyer, N J Beeching, J Scott, K Seddon, S Jamieson, S B Squire, H C Mwandumba, A R O Miller, P D O Davies, and C M Parry The clinical impact of nucleic acid amplification tests on the diagnosis and management of tuberculosis in a British hospital Thorax, April 1, 2008; 63(4): 317 - 321. [Abstract] [Full Text] [PDF]

				F. A. Drobniewski, S. Hoffner, S. Rusch-Gerdes, G. Skenders, V. Thomsen, and the WHO European Laboratory Strengthening Task For Recommended standards for modern tuberculosis laboratory services in Europe Eur. Respir. J., November 1, 2006; 28(5): 903 - 909. [Abstract] [Full Text] [PDF]

				H Maguire, M Ruddy, G Bothamley, B Patel, M Lipman, F Drobniewski, M Yates, and T Brown Multidrug resistance emerging in North London outbreak. Thorax, June 1, 2006; 61(6): 547 - 548. [Full Text] [PDF]

				T D McHugh, C F Pope, C L Ling, S Patel, O J Billington, R D Gosling, M C Lipman, and S H Gillespie Prospective evaluation of BDProbeTec strand displacement amplification (SDA) system for diagnosis of tuberculosis in non-respiratory and respiratory samples J. Med. Microbiol., December 1, 2004; 53(12): 1215 - 1219. [Abstract] [Full Text] [PDF]

				W. C. Yam, C. M. Tam, C. C. Leung, H. L. Tong, K. H. Chan, E. T. Y. Leung, K. C. Wong, W. W. Yew, W. H. Seto, K. Y. Yuen, et al. Direct Detection of Rifampin-Resistant Mycobacterium tuberculosis in Respiratory Specimens by PCR-DNA Sequencing J. Clin. Microbiol., October 1, 2004; 42(10): 4438 - 4443. [Abstract] [Full Text] [PDF]

				C. Piersimoni and C. Scarparo Relevance of Commercial Amplification Methods for Direct Detection of Mycobacterium tuberculosis Complex in Clinical Samples J. Clin. Microbiol., December 1, 2003; 41(12): 5355 - 5365. [Full Text] [PDF]

				F Drobniewski, I Eltringham, C Graham, J G Magee, E G Smith, and B Watt A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK Thorax, September 1, 2002; 57(9): 810 - 816. [Abstract] [Full Text] [PDF]

				T Djuretic, J Herbert, F Drobniewski, M Yates, E G Smith, J G Magee, R Williams, P Flanagan, B Watt, A Rayner, et al. Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999 Thorax, June 1, 2002; 57(6): 477 - 482. [Abstract] [Full Text] [PDF]

				M. Patnaik, K. Liegmann, and J. B. Peter Rapid Detection of Smear-Negative Mycobacterium tuberculosis by PCR and Sequencing for Rifampin Resistance with DNA Extracted Directly from Slides J. Clin. Microbiol., January 1, 2001; 39(1): 51 - 52. [Abstract] [Full Text]